eClinical Tech News

Day One Biopharmaceuticals reported three-year outcomes from the pivotal phase 2 FIREFLY-1 trial of tovorafenib (Ojemda) in pediatric low-grade...

Tonix Pharmaceuticals has secured FDA clearance of an investigational new drug application to study TNX-102 SL (cyclobenzaprine HCl sublingual...

Rakovina Therapeutics unveiled preclinical progress on a new class of CNS‑penetrant, PARP1‑selective inhibitors at the Society for Neuro‑Oncology 2025...

XOMA Royalty Corporation has completed its acquisition of Lava Therapeutics N.V., purchasing all outstanding shares for $1.04 in cash...

Mesoblast will run a pivotal Phase 3 trial with the NIH-funded Blood and Marrow Transplant Clinical Trials Network to...

BioSyent posted double‑digit growth in Q3 2025, extending a profitable run built on in‑licensed, proven brands. Total company sales...

Actimed Therapeutics has licensed exclusive rights to develop and commercialize its cachexia pipeline, including lead candidate s-pindolol benzoate (ACM-001.1),...

Iovance Biotherapeutics has granted inducement stock options covering 164,900 shares to 11 new non-executive employees, effective November 20, 2025....

Valneva reported nine-month 2025 revenues of €127 million, up 9% year over year, alongside a sharp reduction in operating...

BioSyent reported a strong third quarter, with net revenues up 28% to CAD 12.2 million and EBITDA up 27%...